Delayed profound thrombocytopenia after abciximab administration for coronary stenting in acute coronary syndrome. Case reports and review of the literature

Italian Heart Journal

Volumn 6, Issue 8, 2005, Pages 647-651

  Trapolin, Gaia ^a   Savonitto, Stefano ^a   Merlini, Piera Angelica ^a   Gaumi, Maria Teresa ^a   Klugmann, Silvio ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

Platelets; Stents; Thrombocytopenia

Indexed keywords

ABCIXIMAB; ANTICOAGULANT AGENT; CORTICOSTEROID; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY;

ANGIOCARDIOGRAPHY; ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; FOLLOW UP; HEART INFARCTION; HOSPITALIZATION; HUMAN; INSTRUMENTATION; MALE; METHODOLOGY; MIDDLE AGED; PLASMAPHERESIS; RADIOGRAPHY; RISK ASSESSMENT; STENT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY;

ADRENAL CORTEX HORMONES; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; CORONARY ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLASMAPHERESIS; PLATELET COUNT; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STENTS; THROMBOCYTOPENIA; TIME FACTORS;

EID: 33644694184     PISSN: 1129471X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Topol EJ, Byzova TV, Plow EF. Platelet GPIIb-IIIa blockers. Lancet 1999; 353: 227-31.
2. Berkowitz SD, Harrington RA, Rund MM, Tcheng JE. Acute profound thrombocytopenia after c7E3 Fab (abciximab) therapy. Circulation 1997; 95: 809-13.
3. Berkowitz SD, Sane DC, Sigmon KN, et al. Occurrence and clinical significance of trombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. J Am Coll Cardiol 1998; 32: 311-9.
4. Coller BS. Monitoring platelet GP IIb/IIIa (corrected) antagonist therapy. Circulation 1997; 96: 3828-32.
5. Kereiakes DJ, Berkowitz SD, Lincoff AM, et al. Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade. Am Heart J 2000; 140: 74-80.
6. Dasgupta H, Blankenship JC, Wood GC, Frey CM, Demko SL, Menapace FJ. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis. Am Heart J 2000; 140: 206-11.
7. Merlini PA, Rossi M, Menozzi A, et al. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Circulation 2004; 109: 2203-6.
8. Jenkins LA, Lau S, Crawford M, Keung YK. Delayed profound thrombocytopenia after c7E3 Fab (abciximab) therapy. Circulation 1998; 97: 1214-5.
9. Kaluski E, Leitman M, Khiger I, Cotter G. Delayed thrombocytopenia following abciximab therapy. Int J Cardiovasc Intervent 2001; 4: 151-5.
10. Reddy MS, Carmody TJ, Kereiakes DJ. Severe delayed thrombocytopenia associated with abciximab (ReoPro) therapy. Catheter Cardiovasc Interv 2001; 52: 486-8.
11. Sharma S, Bhambi B, Nyitray W, et al. Delayed profound thrombocytopenia presenting 7 days after use of abciximab (Reopro). J Cardiovasc Pharmacol Ther 2002; 7: 21-4.
12. Curtis BR, Divgi A, Garritty M, Aster RH. Delayed thrombocytopenia after treatment with abciximab: a distinct clinical entity associated with the immune response to the drug. J Thromb Haemost 2004; 2: 985-92.
13. Nurden P, Clofent-Sanchez G, Jais C, et al. Delayed immunologic thrombocytopenia induced by abciximab. Thromb Haemost 2004; 92: 820-8.
14. Gawaz M, Neumann FJ, Schomig A. Evaluation of platelet membrane glycoproteins in coronary artery disease: consequences for diagnosis and therapy. Circulation 1999; 99: E1-E11.
15. Madan M, Berkowitz SD. Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitors. Am Heart J 1999; 138: 317-26.
16. Sane DC, Damaraju LV, Topol EJ, et al. Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy. J Am Coll Cardiol 2000; 36: 75-83.
17. Bennett CL, Davidson CJ, Raisch DW, Weinberg PD, Bennett RH, Feldman MD. Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention. Arch Intern Med 1999; 159: 2524-8.
18. Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000; 342: 1773-7.
19. Aster RH. Drug-induced immune thrombocytopenia. An overview of pathogenesis. Semin Hematol 1999; 36 (Suppl 1): 2-6.
20. Rao J, Mascarenhas DA. Successful use of eptifibatide as an adjunct to coronary stenting in a patient with abciximab-associated acute profound thrombocytopenia. J Invasive Cardiol 2001; 13: 471-3.
21. Desai M, Lucore CL. Uneventful use of tirofiban as an adjunct to coronary stenting in a patient with a history of abciximab-associated thrombocytopenia 10 months earlier. J Invasive Cardiol 2000; 12: 109-12.